title: Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis.
authors.forename: E
authors.initials: E
authors.lastname: Kemp
authors.forename: H
authors.initials: H
authors.lastname: Nielsen
authors.forename: L J
authors.initials: LJ
authors.lastname: Petersen
authors.forename: A N
authors.initials: AN
authors.lastname: Gam
authors.forename: J
authors.initials: J
authors.lastname: Dahlager
authors.forename: T
authors.initials: T
authors.lastname: Horn
authors.forename: S
authors.initials: S
authors.lastname: Larsen
authors.forename: S
authors.initials: S
authors.lastname: Olsen
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D005921:Glomerulonephritis / Q000139:chemically induced*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007555:Isoxazoles / Q000009:adverse effects* / Q000627:therapeutic use; D000077339:Leflunomide; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D000077339:Leflunomide; D000068800:Etanercept